K Pharma,Inc. (4896.T)
JPY 756.0
(-1.82%)
JPY 756.0
(-1.82%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.31 Billion JPY | 141.09% |
| 2022 | 1.37 Billion JPY | 568.02% |
| 2021 | 205.76 Million JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 2.78 Billion JPY | -6.15% |
| 2024 Q1 | 2.97 Billion JPY | -10.32% |
| 2023 FY | 3.31 Billion JPY | 141.09% |
| 2023 Q4 | 3.31 Billion JPY | 67.23% |
| 2023 Q3 | 1.98 Billion JPY | -10.96% |
| 2023 Q2 | 2.22 Billion JPY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 6.58 Billion JPY | 49.708% |
| PRISM BioLab Co.,LTD | 1.21 Billion JPY | -173.554% |
| GNI Group Ltd. | 62.39 Billion JPY | 94.689% |
| Linical Co., Ltd. | 18.53 Billion JPY | 82.126% |
| Trans Genic Inc. | 9.81 Billion JPY | 66.223% |
| MEDINET Co., Ltd. | 5.63 Billion JPY | 41.182% |
| Soiken Holdings Inc. | 6.94 Billion JPY | 52.291% |
| Cytori Cell Research Institute, Inc. | 5.81 Billion JPY | 43.024% |
| AnGes, Inc. | 28.89 Billion JPY | 88.53% |
| OncoTherapy Science, Inc. | 867.27 Million JPY | -282.105% |
| Nxera Pharma Co., Ltd. | 157.19 Billion JPY | 97.892% |
| Immuno-Biological Laboratories Co., Ltd. | 1.61 Billion JPY | -104.741% |
| NanoCarrier Co., Ltd. | 5.07 Billion JPY | 34.654% |
| Carna Biosciences, Inc. | 4.34 Billion JPY | 23.816% |
| CanBas Co., Ltd. | 2.43 Billion JPY | -36.215% |
| D. Western Therapeutics Institute, Inc. | 2.37 Billion JPY | -39.628% |
| RaQualia Pharma Inc. | 6.93 Billion JPY | 52.182% |
| Chiome Bioscience Inc. | 1.75 Billion JPY | -89.209% |
| Kidswell Bio Corporation | 5.08 Billion JPY | 34.837% |
| PeptiDream Inc. | 67.12 Billion JPY | 95.063% |
| Oncolys BioPharma Inc. | 2.04 Billion JPY | -62.399% |
| Ribomic Inc. | 3.54 Billion JPY | 6.578% |
| SanBio Company Limited | 5.04 Billion JPY | 34.343% |
| Healios K.K. | 15.15 Billion JPY | 78.133% |
| BrightPath Biotherapeutics Co., Ltd. | 1.23 Billion JPY | -169.367% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 3.01 Billion JPY | -9.877% |
| Delta-Fly Pharma, Inc. | 1.47 Billion JPY | -124.8% |
| StemRIM | 9.08 Billion JPY | 63.503% |
| CellSource Co., Ltd. | 6.87 Billion JPY | 51.831% |
| FunPep Company Limited | 2.49 Billion JPY | -33.028% |
| Kringle Pharma, Inc. | 2.61 Billion JPY | -26.55% |
| Stella Pharma Corporation | 3.82 Billion JPY | 13.263% |
| TMS Co., Ltd. | 3.55 Billion JPY | 6.775% |
| Noile-Immune Biotech Inc. | 5.77 Billion JPY | 42.656% |
| Cuorips Inc. | 6.18 Billion JPY | 46.418% |
| Takara Bio Inc. | 123.2 Billion JPY | 97.31% |
| ReproCELL Incorporated | 9.05 Billion JPY | 63.393% |
| PhoenixBio Co., Ltd. | 2.71 Billion JPY | -22.045% |
| StemCell Institute Inc. | 6.54 Billion JPY | 49.353% |
| Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | 52.582% |
| CellSeed Inc. | 2.46 Billion JPY | -34.396% |